Congenital heart disease is a life-threatening condition affecting nearly 40,000 children in the US every year, and a new $2 million investment could make a big difference.
The investment in Houston-based PolyVascular is part of the Advancium Health Network's CobiCure MedTech initiative, which aims to invest in pediatric medical technologies that can have a "positive impact on children's lives," CobiCure says in a press release.
PolyVascular is developing a non-surgical heart valve that uses a novel polymer to replace faulty heart valves.
"This investment from CobiCure MedTech is a testament to the progress our team has made and acknowledges the need for better solutions for children with congenital heart disease," says pediatric cardiologist Henri Justino, founder and CEO of PolyVascular.
He tells the Houston Chronicle that the company's goal is to eliminate the need for invasive surgeries in children with congenital heart disease, and the $2 million will help the company "demonstrate human clinical readiness."
The CDC estimates that in the US alone, there are more than 7,000 open-heart surgeries every year.
(This summer, a 3-year-old became the first child in the US to undergo a heart transplant.)
A customized collection of grant news from foundations and the federal government from around the Web.
Three social enterprises were recognized at the 2013 President’s Challenge Social Enterprise Award for their major contributions to society. SATA CommHealth and Bliss Restaurant landed Social Enterprise of the Year titles, while Bettr Barista Coffee Academy bagged the award for Social Enterprise Start-up of the Year.